Pharmacokinetic evaluation of decitabine for the treatment of leukemia

Bibliography

• Brenet F, Moh M, Funk P, Genome-Wide Analysis of DNA Methylation Patterns Reveals Dynamic Epigenetic Regulation of the AML Genome After Decitabine Treatment [abstract]. Blood 2009;114:591
   Google Scholar
• Egger G, Gangning L, Aparicio A, Epigenetics in human disease and prospects for epignentic therapy. Nature 2004;429:457-63
   PubMed Web of Science ®Google Scholar
• Baylin SB, Herman JG, Graff JR, Alterations in DNA methylation–a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96
   PubMed Web of Science ®Google Scholar
• Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 1999;59:3730-40
   PubMed Web of Science ®Google Scholar
• Baylin SB, Hoppener JW, de Bustros A, DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas. Cancer Res 1986;46:2917-22
   PubMed Web of Science ®Google Scholar
• Jones PA, Wolkowicz MJ, Rideout WM III, De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines. Proc Natl Acad Sci USA 1990;87:6117-21
   PubMed Web of Science ®Google Scholar
• Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7
   PubMed Web of Science ®Google Scholar
• Corn PG, Kuerbitz SJ, van Noesel MM, Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res 1999;59:3352-6
   PubMed Web of Science ®Google Scholar
• Kawano S, Miller CW, Gombart AF, Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 1999;94:1113-20
   PubMed Web of Science ®Google Scholar
• Issa JPJ, Baylin SB, Herman JG. DNA Methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 1997;11(Suppl 1):S7-11
   PubMed Web of Science ®Google Scholar
• Uchida T, Kinoshita T, Nagai H, Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 1997;90(4):1403-9
   PubMed Web of Science ®Google Scholar
• Herman JG, Civin CI, Issa JP, Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 1997;57:837-41
   PubMed Web of Science ®Google Scholar
• Jones PA, Taylor SM. Cellular differentiation, cytidine analogues and DNA methylation. Cell 1980;20:85-93
   PubMed Web of Science ®Google Scholar
• Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5 azacytosine. Proc Natl Acad Sci U S A 1984;81:6993-7
   PubMed Web of Science ®Google Scholar
• van Groeningen C, Leyva A, O'Brien A, Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 1986;46:4831-6
   PubMed Web of Science ®Google Scholar
• Rivard G, Momparler R, Demers J, Phase I study on 5-aza-2 deoxycytidine in children with acute leukemia. Leuk Res 1981;5:453-62
   PubMed Web of Science ®Google Scholar
• Pliml J, Sorm F. Synthesis of 2-deoxy-D-ribofuranosyl-5-azacytosine. Collect Czech Chem Commun 1964;29:2576-7
   Web of Science ®Google Scholar
• Pinto A, Zagonel V. 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 1993;7(Suppl 1):51-60
   PubMed Web of Science ®Google Scholar
• Momparler RL, Bouchard J, Onetto N, 5-aza-2′-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. Leuk Res 1984;8:181-5
   PubMed Web of Science ®Google Scholar
• Petti M, Mandelli F, Zagonel V, Pilot study of 5-aza-2′-deoxycytidine (decitabine) in the treatment of poor prognosis acute myeloid leukemia patients: preliminary results. Leukemia 1993;7(Suppl 1):36-41
   PubMed Web of Science ®Google Scholar
• Daskalakis M, Nguyen TT, Nguyen C, Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 2002;100:2957-64
   PubMed Web of Science ®Google Scholar
• Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 1998;58:95-101
   PubMed Web of Science ®Google Scholar
• Pinto A, Zagonel V, Attadia V, 5-aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 1989;4(Suppl 2):28-32
   PubMedGoogle Scholar
• Wilson VL, Jones PA, Momparler RL. Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res 1983;43:3493-6
   PubMed Web of Science ®Google Scholar
• Pinto A, Attadia V, Fusco A, 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 1984;64(4):922-9
   PubMed Web of Science ®Google Scholar
• Limonta M, Colombo T, Damia G, Cytotoxic activity and mechanism of action of 5-aza-2′-deoxycytidine in human CML cells. Leuk Res 1993;17:977-82
   PubMed Web of Science ®Google Scholar
• Blum W, Bruner-Klisovic R, Liu S, Phase I study of low dose decitabine in patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. Blood 2005;106:1861
   Google Scholar
• Issa JPJ, Garcia-Manero G, Giles FJ, Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-40
   PubMed Web of Science ®Google Scholar
• Issa JP, Gharibyan V, Cortes J, Phase II study of low-dose decitabine in patients with chronic myeloid leukemia resistant to imatinib mesylate. J Clin Oncol 2005;23:3948-56
   PubMed Web of Science ®Google Scholar
• Sacchi S, Kantarjian HM, O'Brien S, Chronic myeloid leukemia in nonlymphoid blastic phase. Cancer 1999;86:2632-41
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106(8):1794-803
   PubMed Web of Science ®Google Scholar
• WijerMans P, Suciu S, Baila L, Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for Intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC leukemia and german MDS study groups [abstract]. Blood 2008;112:226
   Google Scholar
• Steensma DP, Baer MR, Slack JL, Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009;27:3842-8
   PubMed Web of Science ®Google Scholar
• Rogstad DK, Herring JL, Theruvathu JA, Chemical decomposition of 5-aza-2′-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. Chem Res Toxicol 2009;22:1194-204
   PubMed Web of Science ®Google Scholar
• Chan KK, Giannini DD, Staroscik JA, Sadee W. 5-Azacytidine hydrolysis kinetics measured by high-pressure liquid chromatography and 13C-NMR spectroscopy. J Pharm Sci 1979;68:807-12
   PubMed Web of Science ®Google Scholar
• Hajek M, Votruba I, Holy A, Alpha anomer of 5-aza-2′-deoxycytidine down-regulates hTERT mRNA expression in human leukemia HL-60 cells. Biochem Pharmacol 2008;75:965-72
   PubMed Web of Science ®Google Scholar
• Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008;123:8-13
   PubMed Web of Science ®Google Scholar
• Yoo CB, Jeong S, Egger G, Delivery of 5-aza-2′- deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 2007;67:6400-8
   PubMed Web of Science ®Google Scholar
• Lin KT, Momparler RL, Rivard GE. High performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidine. J Pharm Sci 1981;70:1228-32
   PubMed Web of Science ®Google Scholar
• Liu Z, Marcucci G, Byrd JC, Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2′-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom 2006;20:1117-26
   PubMed Web of Science ®Google Scholar
• Jutterman R, Li E, Jaenisch R. Toxicity of 5-aza-2′- deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994;91:11797-801
   PubMed Web of Science ®Google Scholar
• Rogstad DK, Herring JL, Theruvathu JA, Chemical decomposition of 5-aza-2′-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. Chem Res Toxicol 2009;22:1194-204
   PubMed Web of Science ®Google Scholar
• Momparler R, BouVard D, Momparler L, Pilot phase I–II study on 5-aza-2-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997;8(4):358-68
   PubMed Web of Science ®Google Scholar
• Aparicio A, Eads CA, Leong LA, Phase I trial of continuous infusion 5-aza-2-deoxycytidine. Cancer Chemother Pharmacol 2003;51:231-9
   PubMed Web of Science ®Google Scholar
• Momparler R, Rivard G, Gyger M. Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia. Pharmacol Ther 1985;30:277-86
   PubMed Web of Science ®Google Scholar
• Chabot GG, Rivard GE, Momparler RL. Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2′-deoxycytidine in rabbits and dogs. Cancer Res 1983;43:592-7
   PubMed Web of Science ®Google Scholar
• Dacogen [package insert]. SuperGen, Inc., Dublin, CA; 2010
   Google Scholar
• Amanda F. Cashen AF, Shah AK, et al. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 2008;61:759-66
   PubMed Web of Science ®Google Scholar
• Zagonel, V, Lo Re G, Marotta G, 5-Aza-2′-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 1993;7(Suppl 1):30-5
   PubMedGoogle Scholar
• Wijermans PW, Krulder JW, Huijgens PC, Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997;11:1-5
   PubMed Web of Science ®Google Scholar
• Wijermans P, Lubbert M, Verhoef G, Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-62
   PubMed Web of Science ®Google Scholar
• Wijerman PW, Lubbert M, Verhoef G, An epigenetic approach to the treatment of advanced MDS;the experience with DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005;84(Suppl 1):9-17
   PubMedGoogle Scholar
• Cheson BD, Bennett JM, Kantarjian H, Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96(12):3671-4
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, Results of a randomized study of 3 schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-7
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenber PL, Bennett JM, Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-25
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Steensma DP. Myelodysplastic syndrome patients obtaining a cytogenetic response to outpatient decitabine experience improved hematological responses and longer survival: additional analyses from the ADOPT trial [abstract]. Blood 2009;114:3817
   Google Scholar
• Kantarjian HM, O'Brien S, Huang X, Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007;109:1133-7
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, ; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32
   PubMed Web of Science ®Google Scholar
• Oki Y, Kantarjian HM, O'Brien S, Phase II Study of decitabine in combination with imatinib mesylate in patients with accelerated (AP) or blastic phase (BP) of chronic myeloid leukemia (CML) [abstract]. Blood 2005;106:1099
   Google Scholar
• Willemze R, Archimbaud E, Muus P. Preliminary results with 5-aza-2′-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. Leukemia 1993;7(Suppl 1):49-50
   PubMedGoogle Scholar
• Willemze R, Suciu S, Archimbaud E, A randomized phase II study on the efects of 5-Aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia 1997;11(Suppl 1):24-7
   Google Scholar
• Issa JPJ, Saba HI, Garcia-Manero G, Decitabine in older patients with acute myeloid leukemia (AML) [abstract]. J Clin Oncol 2007;25:7021
   Google Scholar
• Danilov AV, Smith H, Relias V, Outpatient decitabine in elderly patients with acute myeloid leukemia (AML) [abstract]. Blood 2009;114:4144
   Google Scholar
• Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010;28(4):556-61
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G. Modifying the epigenome as a therapeutic strategy in myelodysplasia. Hematology Am Soc Hematol Educ Program 2007;2007(1):405-11
   Google Scholar
• Kondo Y, Shen L, Yan PS, Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proc Natl Acad Sci USA 2004;101:7398-403
   PubMed Web of Science ®Google Scholar
• Schlesinger Y, Straussman R, Keshet I, Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007;39:232-6
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Strupp C, Aivado M, Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004;104:1266-9
   PubMed Web of Science ®Google Scholar
• Yang H, Hoshino K, Sanchez-Gonzalez B, Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res 2005;29(7):739-48
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108(10):3271-9
   PubMed Web of Science ®Google Scholar
• Blum W, Klisovic RB, Hackanson B, Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25:3884-91
   PubMed Web of Science ®Google Scholar
• Issa JP, Castoro R, Ravandi-Kashani F, Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML [abstract]. Blood 2008;112:228
   Web of Science ®Google Scholar
• Ravandi F, Faderl S, Thomas D, Phase I study of suberoylanilide hydroxamic acid (SAHA) and decitabine in patients with relapsed, refractory or poor prognosis leukemia [abstract]. Blood 2007;110:897
   Web of Science ®Google Scholar
• Kirschbaum M, Gojo I, Goldberg SL, Vorinostat in combination with decitabine for the treatment of relapsed or newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS): a phase I, dose-escalation study [abstract]. Blood 2009;114:2089
   Google Scholar
• Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21(35):5483-95
   PubMed Web of Science ®Google Scholar
• Atallah E, Kantarjian H, Garcia-Manero G. The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother 2007;8(1):65-73
   PubMed Web of Science ®Google Scholar
• Jabbour E, Garcia-Manero G, Batty N, Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010;116(16):3830-4
   PubMed Web of Science ®Google Scholar
• Borthakur G, Ahdab SE, Ravandi F, Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008;49:690-5
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance epidemiology and end results stat facts sheets. cancer: acute meyloid leukemia. Available from: http://seer.cancer.gov/statfacts/html/clyl.html [Accessed 1 Sep 2010]
   Google Scholar
• Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30
   PubMed Web of Science ®Google Scholar
• Dillman RO, Davis RB, Green MR, A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991;78:2520-6
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Sun Z, Yao X, Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249-59
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Ossenkoppele GJ, van Putten W, High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:1235-48
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Davis RB, Schiffer CA, Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903
   PubMed Web of Science ®Google Scholar
• Cassileth PA, Lynch E, Hines JD, Varying intensity of post remission therapy in acute myeloid leukemia. Blood 1992;79:1924-30
   PubMed Web of Science ®Google Scholar
• Elonen E, Almqvist A, Hanninen A, Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group. Leukemia 1998;12:1041-8
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, Age and acute myeloid leukemia. Blood 2006;107:3481-5
   PubMed Web of Science ®Google Scholar
• Menzin J, Boulanger L, Karsten V, Effects of initial treatment on survival among elderly AML patients: findings from the SEER-Medicare Database [abstract]. Blood 2006;108:1973
   Google Scholar
• Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007;25(14):1908-15
   PubMed Web of Science ®Google Scholar
• Rowe JM, Neuberg D, Friedenberg W, Eastern Cooperative Oncology. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103(2):479-85
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O'Brien S, Cortes J, Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090-8
   PubMed Web of Science ®Google Scholar
• Lang K, Earle C, Foster T, Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging 2006;22(11):943-55
   Web of Science ®Google Scholar
• de Lima M, Ghaddar H, Pierce S, Estey E. Treatment of newly-diagnosed acute myeloid leukemia in patients aged 80 years and above. Br J Haematol 1996;93(4):89-93
   PubMedGoogle Scholar
• Goldstone AH, Burnett A, Wheatley K, Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML 11 trial. Blood 2001;98(5):1302-11
   PubMed Web of Science ®Google Scholar
• Burnett AK, Milligan D, Prentice AG, A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:1114-24
   PubMed Web of Science ®Google Scholar
• Cassileth PA, Harrington DP, Hines JD, Maintenance chemotherapy prolongs remission duration in adult acute non-lymphocytic leukemia. J Clin Oncol 1988;6:583-7
   PubMed Web of Science ®Google Scholar
• Robles C, Kim KM, Oken MM, Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483). Leukemia 2000;14:1349-53
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Suciu S, Archimbaud E, Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of the European Organisation for the Research and Treatment of Cancer and the Dutch Belgium Hemato-Oncology Cooperative Group. Blood 1997;90:2952-61
   PubMed Web of Science ®Google Scholar
• Rees JKH, Gray RG, Wheatley K. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost: principal report of the Medical Research Council's AML9 study. Br J Haematol 1996;94:89-98
   PubMed Web of Science ®Google Scholar
• Lubbert M, Bertz H, Ruter B, Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 2009;44:585-8
   PubMed Web of Science ®Google Scholar
• Yang H, Thomas DA, Rytting ME, Phase I study of frequent low-dose administration of decitabine, alone or in combination with hyperCVAD, in relapsed or refractory acute lymphocytic leukemia (ALL) [abstract]. J Clin Oncol 2007;25:7072
   Web of Science ®Google Scholar
• Blum W, Garzon R, Klisovik RB, Clinical response and miR-29b predictive significance in older AML patients treated with 10-day schedule of decitabine. PNAS 2010;107:7473-8
   PubMed Web of Science ®Google Scholar